GSK plc (NYSE:GSK) Shares Sold by CWA Asset Management Group LLC

CWA Asset Management Group LLC lessened its holdings in GSK plc (NYSE:GSK) by 65.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,210 shares of the pharmaceutical company’s stock after selling 30,397 shares during the quarter. CWA Asset Management Group LLC’s holdings in GSK were worth $548,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. FMR LLC lifted its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC increased its position in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares during the period. Primecap Management Co. CA lifted its stake in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its holdings in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after acquiring an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC grew its position in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Down 1.1 %

Shares of NYSE:GSK opened at $33.72 on Thursday. The company has a 50 day moving average of $34.52 and a 200-day moving average of $38.27. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market cap of $69.89 billion, a P/E ratio of 21.90, a P/E/G ratio of 1.52 and a beta of 0.63. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.66%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio (DPR) is presently 98.70%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Seven equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.